Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.13 to $3.22
• 50-Day Range: $2.90 to $3.37
• 52-Week Range: $2.75 to $4.15
• Volume: 258,979 shs
• Average Volume: 270,827 shs
• Market Capitalization: $273.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.88
• Consensus Rating: Moderate Buy

Atea Pharmaceuticals Stock Analysis - MarketRank™

Atea Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 495th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Atea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atea Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atea Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atea Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.09% of the float of Atea Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Atea Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Atea Pharmaceuticals has recently decreased by 2.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atea Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Atea Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.09% of the float of Atea Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Atea Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Atea Pharmaceuticals has recently decreased by 2.71%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.01

News Sentiment

Atea Pharmaceuticals has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Atea Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVIR Stock Analysis - Frequently Asked Questions

How have AVIR shares performed this year?

Atea Pharmaceuticals' stock was trading at $3.35 on January 1st, 2025. Since then, AVIR shares have decreased by 4.5% and is now trading at $3.20.
View the best growth stocks for 2025 here.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced its quarterly earnings data on Thursday, March, 6th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05.

When did Atea Pharmaceuticals IPO?

Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

Who are Atea Pharmaceuticals' major shareholders?

Top institutional shareholders of Atea Pharmaceuticals include BML Capital Management LLC (9.01%), Tang Capital Management LLC (5.67%), Vanguard Group Inc. (5.53%) and Geode Capital Management LLC (2.27%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Bruce Polsky and Wayne Foster.
View institutional ownership trends.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atea Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 3/26/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVIR
• CIK: 1593899
• Web: www.ateapharma.com
• Phone: 857-284-8891
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.88
• High Stock Price Target: $6.88
• Low Stock Price Target: $6.88
• Potential Upside/Downside: +115.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-135,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.90%
• Return on Assets: -32.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.33
• Quick Ratio: 19.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.65 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 85,525,000
• Free Float: 69,429,000
• Market Cap: $273.68 million
• Optionable: Optionable
• Beta: 0.18